CellCentric Ltd.
CellCentric Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | Multiple Myeloma Refractory; Multiple Myeloma in Relapse | Recruiting | Phase 2 | 2026-09-21 | NCT07096778 | |
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma | Multiple Myeloma Refractory; Multiple Myeloma in Relapse | Recruiting | Phase 3 | 2026-08-19 | NCT07772024 | |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, monoclonal gammopathy, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT04068597 |